GH 31
Alternative Names: GH-31Latest Information Update: 22 Jun 2024
At a glance
- Originator Suzhou Genhouse Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action MAT2A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 22 Jun 2022 Preclinical trials in Cancer in China (unspecified route) (Suzhou Genhouse Bio pipeline, June 2022)
- 01 Sep 2021 GH 31 is available for licensing as of 26 Aug 2021. https://www.genhousebio.com/en/cooperation/index.html